title: Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
abstract: OBJECTIVE
  The present study uses the data from a large survey conducted to examine the general practice of Spanish psychiatrists on the use of antidepressant combinations in the treatment of depressive disorders.
  
  
  METHODS
  The sample was drawn from specialists and psychiatric residents practicing in Spain who were respondents to a questionnaire distributed during an annual national psychiatry meeting and sent by mail.
  
  
  RESULTS
  A total of 1032 questionnaires were collected; following the data-filtering, 831 were analysed. Most psychiatrists (89%) believe that many patients do not respond to the first treatment; in such cases of non-response, 58% choose a combination of antidepressants as the next treatment option. Reasons for using the combined treatments include greater efficacy (57%), overcoming resistance to the first antidepressant (27%), faster onset of action (21%) and avoidance of side effects (17%). The most sought after pharmacological profile was serotonergic-noradrenergic (96%) and the most popular combinations were selective serotonin reuptake inhibitor (SSRI) + mirtazapine, SSRI + reboxetine and SSRI + tricyclic antidepressant.
  
  
  CONCLUSIONS
  Antidepressant combinations are frequently used in clinical practice. Pharmacological profiles are always considered and SSRIs + mirtazapine is the option usually chosen.
authors.affiliation: Hospital General Yagüe, Burgos, Spain. jjgandara@terra.es
authors.forename: J
authors.initials: J
authors.lastname: de la Gándara
authors.forename: L
authors.initials: L
authors.lastname: Agüera
authors.forename: J E
authors.initials: JE
authors.lastname: Rojo
authors.forename: S
authors.initials: S
authors.lastname: Ros
authors.forename: J M
authors.initials: JM
authors.lastname: de Pedro
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003625:Data Collection; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D006801:Humans; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D010818:Practice Patterns, Physicians'; D011570:Psychiatry / Q000706:statistics & numerical data; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013030:Spain; D011795:Surveys and Questionnaires
chemical_list: D000928:Antidepressive Agents; D008803:Mianserin; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors